Intrahepatic cholangiocarcinoma
Conditions
Interventions
DEB-TACE:Irinotecan loaded on drug-loaded microspheres
C-TACE:Lipiodol embolization combined with irinotecan infusion chemotherapy
Sponsors
Intervention Department, Fifth Medical Center, General Hospital of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? Meet the diagnostic criteria, age 18-75, both men and women can be enrolled in the group; ? TNM stage was stage II and III, and at least one lesion could be measured; ? Child-Pugh A/B grade (= 9 points); ? Physical fitness score (ECOG score) of Eastern Cancer Collaboration Group = 2; ? TBIL =3 mg/L, ALT/AST =5 times the upper limit of normal value, prothrombin activity = 40%, renal function =1.5 times normal value, blood routine neutrophil absolute value =1.5 x 10^9/L, HGB =90 g/L, and the expected survival time is at least 6 weeks; ? Signing consent before treatment.
Exclusion criteria
Exclusion criteria: ? Participation in other clinical trials/drug trials within 3 months before admission; ? Massive ascites or severe jaundice; ? Extremely ill or cachexia; ? Severe multiple organ dysfunction; ? Active infections, especially those associated with biliary tract infections; ? Previous patients receiving embolic liver radiotherapy and other ablative therapies; ? Upper gastrointestinal bleeding occurred one month before the portal vein trunk was completely blocked with a liver tumor load greater than 70%; ? Human immunodeficiency virus (HIV) infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Five year survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;local control rate;complete remission rate; | — |
Countries
China
Contacts
Public ContactHui Xie
Fifth Medical Center of PLA General Hospital
Outcome results
None listed